AGS7
MCID: ACR084
MIFTS: 30

Aicardi-Goutieres Syndrome 7 (AGS7)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Aicardi-Goutieres Syndrome 7

MalaCards integrated aliases for Aicardi-Goutieres Syndrome 7:

Name: Aicardi-Goutieres Syndrome 7 57 72 29 6 70
Ags7 57 72
Aicardi-Goutieres Syndrome, Type 7 39

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Miscellaneous:
incomplete penetrance
variable severity
onset in infancy or early childhood

Inheritance:
autosomal dominant


HPO:

31
aicardi-goutieres syndrome 7:
Inheritance autosomal dominant inheritance
Onset and clinical course variable expressivity incomplete penetrance


Classifications:



Summaries for Aicardi-Goutieres Syndrome 7

OMIM® : 57 Aicardi-Goutieres syndrome-7 (AGS7) is an autosomal dominant inflammatory disorder characterized by severe neurologic impairment. Most patients present in infancy with delayed psychomotor development, axial hypotonia, spasticity, and brain imaging changes, including basal ganglia calcification, cerebral atrophy, and deep white matter abnormalities. Laboratory evaluation shows increased alpha-interferon (IFNA1; 147660) activity with upregulation of interferon signaling and interferon-stimulated gene expression. Some patients may have normal early development followed by episodic neurologic regression (summary by Rice et al., 2014). For a phenotypic description and a discussion of genetic heterogeneity of Aicardi-Goutieres syndrome, see AGS1 (225750). (615846) (Updated 20-May-2021)

MalaCards based summary : Aicardi-Goutieres Syndrome 7, is also known as ags7. An important gene associated with Aicardi-Goutieres Syndrome 7 is IFIH1 (Interferon Induced With Helicase C Domain 1). Affiliated tissues include eye and brain, and related phenotypes are abnormality of eye movement and developmental regression

UniProtKB/Swiss-Prot : 72 Aicardi-Goutieres syndrome 7: A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

Related Diseases for Aicardi-Goutieres Syndrome 7

Symptoms & Phenotypes for Aicardi-Goutieres Syndrome 7

Human phenotypes related to Aicardi-Goutieres Syndrome 7:

31 (show all 23)
# Description HPO Frequency HPO Source Accession
1 abnormality of eye movement 31 occasional (7.5%) HP:0000496
2 developmental regression 31 occasional (7.5%) HP:0002376
3 splenomegaly 31 occasional (7.5%) HP:0001744
4 hepatomegaly 31 occasional (7.5%) HP:0002240
5 microcephaly 31 occasional (7.5%) HP:0000252
6 thrombocytopenia 31 occasional (7.5%) HP:0001873
7 nephrotic syndrome 31 occasional (7.5%) HP:0000100
8 seizure 31 occasional (7.5%) HP:0001250
9 increased circulating antibody level 31 occasional (7.5%) HP:0010702
10 intellectual disability 31 HP:0001249
11 global developmental delay 31 HP:0001263
12 absent speech 31 HP:0001344
13 intrauterine growth retardation 31 HP:0001511
14 irritability 31 HP:0000737
15 dystonia 31 HP:0001332
16 vasculitis 31 HP:0002633
17 feeding difficulties 31 HP:0011968
18 spastic tetraparesis 31 HP:0001285
19 cerebral atrophy 31 HP:0002059
20 generalized hypotonia 31 HP:0001290
21 muscular hypotonia of the trunk 31 HP:0008936
22 atopic dermatitis 31 HP:0001047
23 basal ganglia calcification 31 HP:0002135

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neurologic Central Nervous System:
dystonia
cerebral atrophy
basal ganglia calcification
mental retardation
seizures (in some patients)
more
Muscle Soft Tissue:
hypotonia

Hematology:
thrombocytopenia (in some patients)

Growth Other:
intrauterine growth retardation (iugr)

Abdomen Spleen:
splenomegaly (in some patients)

Head And Neck Eyes:
abnormal ocular movements (in some patients)

Skin Nails Hair Skin:
vasculitis
atopic dermatitis
lack of chilblain lesions

Abdomen Gastrointestinal:
poor feeding

Head And Neck Head:
microcephaly (in some patients)

Abdomen Liver:
hepatomegaly (in some patients)

Immunology:
upregulation of alpha-interferon-stimulated genes
autoantibodies (in some patients)
lupus-like syndrome (in some patients)
hyperinflammatory state
increased alpha-interferon activity
more
Genitourinary Kidneys:
nephrotic syndrome (1 patient)

Clinical features from OMIM®:

615846 (Updated 20-May-2021)

Drugs & Therapeutics for Aicardi-Goutieres Syndrome 7

Search Clinical Trials , NIH Clinical Center for Aicardi-Goutieres Syndrome 7

Genetic Tests for Aicardi-Goutieres Syndrome 7

Genetic tests related to Aicardi-Goutieres Syndrome 7:

# Genetic test Affiliating Genes
1 Aicardi-Goutieres Syndrome 7 29 IFIH1

Anatomical Context for Aicardi-Goutieres Syndrome 7

MalaCards organs/tissues related to Aicardi-Goutieres Syndrome 7:

40
Eye, Brain

Publications for Aicardi-Goutieres Syndrome 7

Articles related to Aicardi-Goutieres Syndrome 7:

(show all 15)
# Title Authors PMID Year
1
An extremely severe case of Aicardi-Goutières syndrome 7 with a novel variant in IFIH1. 6 57 61
30965144 2020
2
Aicardi goutières syndrome is associated with pulmonary hypertension. 57 6
30219631 2018
3
Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. 6 57
25243380 2014
4
Aicardi-Goutières syndrome is caused by IFIH1 mutations. 6 57
24995871 2014
5
Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. 6 57
24686847 2014
6
Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. 6
31898846 2020
7
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis. 6
30593198 2018
8
Autosomal-dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. 6
29782060 2018
9
Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy. 6
28605144 2017
10
Further evidence for specific IFIH1 mutation as a cause of Singleton-Merten syndrome with phenotypic heterogeneity. 6
28319323 2017
11
Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes. 6
26284909 2015
12
A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome. 6
25620204 2015
13
Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients. 61
32243572 2020
14
Generation of three isogenic induced Pluripotent Stem Cell lines (iPSCs) from fibroblasts of a patient with Aicardi Goutières Syndrome carrying a c.2471G>A dominant mutation in IFIH1 gene. 61
31698194 2019
15
Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières Syndrome and Beyond. 61
27643693 2016

Variations for Aicardi-Goutieres Syndrome 7

ClinVar genetic disease variations for Aicardi-Goutieres Syndrome 7:

6 (show top 50) (show all 314)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IFIH1 NM_022168.4(IFIH1):c.2159G>A (p.Arg720Gln) SNV Pathogenic 137621 rs587777445 GRCh37: 2:163133342-163133342
GRCh38: 2:162276832-162276832
2 IFIH1 NM_022168.4(IFIH1):c.2336G>A (p.Arg779His) SNV Pathogenic 137622 rs587777446 GRCh37: 2:163130423-163130423
GRCh38: 2:162273913-162273913
3 IFIH1 NM_022168.4(IFIH1):c.1009A>G (p.Arg337Gly) SNV Pathogenic 137623 rs587777447 GRCh37: 2:163144731-163144731
GRCh38: 2:162288221-162288221
4 IFIH1 NM_022168.4(IFIH1):c.2335C>T (p.Arg779Cys) SNV Pathogenic 137624 rs587777448 GRCh37: 2:163130424-163130424
GRCh38: 2:162273914-162273914
5 IFIH1 NM_022168.4(IFIH1):c.1483G>A (p.Gly495Arg) SNV Pathogenic 137625 rs672601336 GRCh37: 2:163137879-163137879
GRCh38: 2:162281369-162281369
6 IFIH1 NM_022168.4(IFIH1):c.1354G>A (p.Ala452Thr) SNV Pathogenic 140750 rs587777575 GRCh37: 2:163138008-163138008
GRCh38: 2:162281498-162281498
7 IFIH1 NM_022168.4(IFIH1):c.1114C>T (p.Leu372Phe) SNV Pathogenic 140751 rs587777576 GRCh37: 2:163139068-163139068
GRCh38: 2:162282558-162282558
8 IFIH1 NM_022168.4(IFIH1):c.1738C>T (p.Gln580Ter) SNV Pathogenic 587512 rs774888783 GRCh37: 2:163134742-163134742
GRCh38: 2:162278232-162278232
9 IFIH1 NM_022168.4(IFIH1):c.2465G>A (p.Arg822Gln) SNV Pathogenic 189338 rs376048533 GRCh37: 2:163128887-163128887
GRCh38: 2:162272377-162272377
10 IFIH1 NM_022168.4(IFIH1):c.2465G>A (p.Arg822Gln) SNV Pathogenic 189338 rs376048533 GRCh37: 2:163128887-163128887
GRCh38: 2:162272377-162272377
11 IFIH1 NM_022168.4(IFIH1):c.2439A>T (p.Glu813Asp) SNV Pathogenic 623488 rs1559810905 GRCh37: 2:163130320-163130320
GRCh38: 2:162273810-162273810
12 IFIH1 NM_022168.4(IFIH1):c.2336G>A (p.Arg779His) SNV Pathogenic 137622 rs587777446 GRCh37: 2:163130423-163130423
GRCh38: 2:162273913-162273913
13 IFIH1 NM_022168.4(IFIH1):c.2342G>A (p.Gly781Glu) SNV Pathogenic 812533 rs1576222845 GRCh37: 2:163130417-163130417
GRCh38: 2:162273907-162273907
14 IFIH1 NM_022168.4(IFIH1):c.2404A>G (p.Asn802Asp) SNV Pathogenic 812534 rs1576222803 GRCh37: 2:163130355-163130355
GRCh38: 2:162273845-162273845
15 IFIH1 NM_022168.4(IFIH1):c.2407A>T (p.Ile803Phe) SNV Pathogenic 812535 rs774958328 GRCh37: 2:163130352-163130352
GRCh38: 2:162273842-162273842
16 IFIH1 NM_022168.4(IFIH1):c.2471G>A (p.Arg824Lys) SNV Pathogenic 812536 rs1238832404 GRCh37: 2:163128881-163128881
GRCh38: 2:162272371-162272371
17 IFIH1 NM_022168.4(IFIH1):c.2486C>G (p.Thr829Ser) SNV Pathogenic 812537 rs765887304 GRCh37: 2:163128866-163128866
GRCh38: 2:162272356-162272356
18 IFIH1 NM_022168.4(IFIH1):c.2544T>G (p.Asp848Glu) SNV Pathogenic 812538 rs1576222015 GRCh37: 2:163128808-163128808
GRCh38: 2:162272298-162272298
19 IFIH1 NM_022168.4(IFIH1):c.2561T>A (p.Met854Lys) SNV Pathogenic 812539 rs138373022 GRCh37: 2:163128791-163128791
GRCh38: 2:162272281-162272281
20 IFIH1 NM_022168.4(IFIH1):c.2866A>G (p.Ile956Val) SNV Pathogenic 812540 rs1576219706 GRCh37: 2:163124021-163124021
GRCh38: 2:162267511-162267511
21 IFIH1 NM_022168.4(IFIH1):c.1764dup (p.Ala589fs) Duplication Pathogenic 541791 rs553669430 GRCh37: 2:163134715-163134716
GRCh38: 2:162278205-162278206
22 IFIH1 NM_022168.4(IFIH1):c.992C>G (p.Thr331Arg) SNV Pathogenic 812522 rs1576229572 GRCh37: 2:163144748-163144748
GRCh38: 2:162288238-162288238
23 IFIH1 NM_022168.4(IFIH1):c.992C>T (p.Thr331Ile) SNV Pathogenic 812523 rs1576229572 GRCh37: 2:163144748-163144748
GRCh38: 2:162288238-162288238
24 IFIH1 NM_022168.4(IFIH1):c.1165G>A (p.Gly389Arg) SNV Pathogenic 812524 rs1576227162 GRCh37: 2:163139017-163139017
GRCh38: 2:162282507-162282507
25 IFIH1 NM_022168.4(IFIH1):c.1178A>C (p.Asp393Ala) SNV Pathogenic 812525 rs587777449 GRCh37: 2:163139004-163139004
GRCh38: 2:162282494-162282494
26 IFIH1 NM_022168.4(IFIH1):c.1331A>G (p.Glu444Gly) SNV Pathogenic 812526 rs1576226728 GRCh37: 2:163138031-163138031
GRCh38: 2:162281521-162281521
27 IFIH1 NM_022168.4(IFIH1):c.1347C>G (p.Asn449Lys) SNV Pathogenic 812527 rs753383954 GRCh37: 2:163138015-163138015
GRCh38: 2:162281505-162281505
28 IFIH1 NM_022168.4(IFIH1):c.1465G>A (p.Ala489Thr) SNV Pathogenic 812528 rs1576226604 GRCh37: 2:163137897-163137897
GRCh38: 2:162281387-162281387
29 IFIH1 NM_022168.4(IFIH1):c.1747A>G (p.Ile583Val) SNV Pathogenic 812529 rs753599401 GRCh37: 2:163134733-163134733
GRCh38: 2:162278223-162278223
30 IFIH1 NM_022168.4(IFIH1):c.2156C>T (p.Ala719Val) SNV Pathogenic 812530 rs1576224269 GRCh37: 2:163133345-163133345
GRCh38: 2:162276835-162276835
31 IFIH1 NM_022168.4(IFIH1):c.2317G>C (p.Glu773Gln) SNV Pathogenic 812531 rs201472224 GRCh37: 2:163130442-163130442
GRCh38: 2:162273932-162273932
32 IFIH1 NM_022168.4(IFIH1):c.2016del (p.Asp673fs) Deletion Pathogenic 580488 rs773033563 GRCh37: 2:163133953-163133953
GRCh38: 2:162277443-162277443
33 IFIH1 NM_022168.4(IFIH1):c.713G>A (p.Trp238Ter) SNV Pathogenic 1032134 GRCh37: 2:163163275-163163275
GRCh38: 2:162306765-162306765
34 IFIH1 NM_022168.4(IFIH1):c.2016_2019AGAT[1] (p.Arg674fs) Microsatellite Pathogenic 377097 rs569337014 GRCh37: 2:163133946-163133949
GRCh38: 2:162277436-162277439
35 IFIH1 NM_022168.4(IFIH1):c.1517T>A (p.Ile506Asn) SNV Likely pathogenic 626276 rs1320095792 GRCh37: 2:163137845-163137845
GRCh38: 2:162281335-162281335
36 IFIH1 NM_022168.4(IFIH1):c.2336G>T (p.Arg779Leu) SNV Likely pathogenic 812532 rs587777446 GRCh37: 2:163130423-163130423
GRCh38: 2:162273913-162273913
37 IFIH1 NM_022168.4(IFIH1):c.716dup (p.Met240fs) Duplication Likely pathogenic 587596 rs1558875029 GRCh37: 2:163163271-163163272
GRCh38: 2:162306761-162306762
38 IFIH1 NM_022168.4(IFIH1):c.986T>C (p.Leu329Pro) SNV Likely pathogenic 577615 rs923064561 GRCh37: 2:163144754-163144754
GRCh38: 2:162288244-162288244
39 IFIH1 NM_022168.4(IFIH1):c.1178A>T (p.Asp393Val) SNV Likely pathogenic 137626 rs587777449 GRCh37: 2:163139004-163139004
GRCh38: 2:162282494-162282494
40 IFIH1 NM_022168.4(IFIH1):c.2936T>G (p.Leu979Trp) SNV Likely pathogenic 541770 rs1553696482 GRCh37: 2:163123852-163123852
GRCh38: 2:162267342-162267342
41 IFIH1 NM_022168.4(IFIH1):c.2524G>A (p.Glu842Lys) SNV Conflicting interpretations of pathogenicity 474952 rs79324540 GRCh37: 2:163128828-163128828
GRCh38: 2:162272318-162272318
42 IFIH1 NM_022168.4(IFIH1):c.1641+1G>C SNV Conflicting interpretations of pathogenicity 261563 rs35337543 GRCh37: 2:163136505-163136505
GRCh38: 2:162279995-162279995
43 IFIH1 NM_022168.4(IFIH1):c.1066C>A (p.Pro356Thr) SNV Conflicting interpretations of pathogenicity 541784 rs150317197 GRCh37: 2:163144674-163144674
GRCh38: 2:162288164-162288164
44 IFIH1 NM_022168.4(IFIH1):c.2362G>A (p.Ala788Thr) SNV Conflicting interpretations of pathogenicity 541788 rs148369169 GRCh37: 2:163130397-163130397
GRCh38: 2:162273887-162273887
45 IFIH1 NM_022168.4(IFIH1):c.478A>G (p.Asn160Asp) SNV Conflicting interpretations of pathogenicity 625959 rs74162075 GRCh37: 2:163167419-163167419
GRCh38: 2:162310909-162310909
46 IFIH1 NM_022168.4(IFIH1):c.2863C>G (p.Gln955Glu) SNV Conflicting interpretations of pathogenicity 705603 rs144455277 GRCh37: 2:163124024-163124024
GRCh38: 2:162267514-162267514
47 IFIH1 NM_022168.4(IFIH1):c.1879G>T (p.Glu627Ter) SNV Conflicting interpretations of pathogenicity 377048 rs35744605 GRCh37: 2:163134090-163134090
GRCh38: 2:162277580-162277580
48 IFIH1 NM_022168.4(IFIH1):c.1764del (p.Ala589fs) Deletion Uncertain significance 987915 GRCh37: 2:163134716-163134716
GRCh38: 2:162278206-162278206
49 IFIH1 NM_022168.4(IFIH1):c.769+3A>G SNV Uncertain significance 987916 GRCh37: 2:163163216-163163216
GRCh38: 2:162306706-162306706
50 IFIH1 NM_022168.4(IFIH1):c.2321T>A (p.Val774Asp) SNV Uncertain significance 996881 GRCh37: 2:163130438-163130438
GRCh38: 2:162273928-162273928

UniProtKB/Swiss-Prot genetic disease variations for Aicardi-Goutieres Syndrome 7:

72
# Symbol AA change Variation ID SNP ID
1 IFIH1 p.Arg337Gly VAR_071375 rs587777447
2 IFIH1 p.Leu372Phe VAR_071376 rs587777576
3 IFIH1 p.Asp393Val VAR_071377 rs587777449
4 IFIH1 p.Ala452Thr VAR_071378 rs587777575
5 IFIH1 p.Gly495Arg VAR_071379 rs672601336
6 IFIH1 p.Arg720Gln VAR_071380 rs587777445
7 IFIH1 p.Arg779Cys VAR_071381 rs587777448
8 IFIH1 p.Arg779His VAR_071382 rs587777446

Expression for Aicardi-Goutieres Syndrome 7

Search GEO for disease gene expression data for Aicardi-Goutieres Syndrome 7.

Pathways for Aicardi-Goutieres Syndrome 7

GO Terms for Aicardi-Goutieres Syndrome 7

Sources for Aicardi-Goutieres Syndrome 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....